



Revolutionizing the Biological Landscape: the Power of Genome Editing

Deeti Das¹, Sudipta Chakraborty², Moumita Mukherjee³, Susoma Garai⁴, Semanti Ghosh⁵,
Bidisha Ghosh⁶, Subhasis Sarkar⁷, Suranjana Sarkar^{8*}

^{1,2,3,4,5}Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal, India.

^{6,7,8*}Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal, India.

***Corresponding Author:** Suranjana Sarkar

*Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal, India. e-mail: suranjanas@svu.ac.in

Article History	Abstract
<p>Received: 30/09/2023 Revised: 15/10/2023 Accepted: 30/10/2023</p>	<p>In recent decades, the advent of genome editing has brought about profound transformations in biology, allowing for precise modifications to the genetic material of living organisms beyond traditional genetic manipulation methods. This summary explores the vast potential, diverse applications, and ethical considerations associated with genome editing. Led by CRISPR-Cas9, this technology revolutionizes genetic engineering by providing unparalleled accuracy and versatility. Scientists can now manipulate genes with unprecedented precision, impacting various fields such as agriculture and medicine. Genome editing facilitates the creation of genetically modified organisms with desirable traits, from enhancing crop disease resistance to pioneering human therapies. Moreover, it sheds light on gene function, offering crucial biological insights. Despite its transformative potential, ethical concerns accompany genome editing, especially in terms of editing the germ line and its implications for future generations. This necessitates ongoing discussions to address unintended consequences, highlighting the importance of responsible use. Ultimately, genome editing represents a revolutionary advancement with the potential to transform agriculture, medicine, and our understanding of life. Moving forward, inclusive dialogues involving scientists, ethicists, policymakers, and the public are essential to ensure the responsible application of genome editing for the benefit of humanity and the environment.</p>
<p>CC License CC-BY-NC-SA 4.0</p>	<p>Keywords: CRISPR-Cas9, DNA, Genome editing, Genetic engineering, Nuclease</p>

Introduction

Genome editing, identified as a groundbreaking scientific advancement, stands out as one of the most transformative technologies of the 21st century. At its core, genome editing involves the precise modification of an organism's DNA, providing unparalleled control over the genetic makeup of living entities, including humans. This remarkable capability carries significant implications across diverse fields, spanning medicine,

agriculture, biotechnology, and ethics. By facilitating scientists in adding, removing, or modifying genes with exceptional precision, genome editing opens up avenues for various applications, ranging from groundbreaking therapies for genetic disorders to the development of genetically enhanced crops. As we delve into the intricacies and potential consequences of genome editing, it becomes increasingly apparent that we are on the verge of an era where the fundamental blueprint of life can be redefined. This overview will explore the scientific principles, applications, ethical challenges, and future outlook of genome editing, shedding light on both its remarkable potential and the profound ethical and societal challenges it introduces (Gaj et al., 2023).

Types of Genome Editing

The revolution in genome editing has been driven by three pivotal technologies: CRISPR-Cas9, TALE nucleases, and zinc-finger nucleases. While these advancements hold transformative potential, several challenges, particularly in effectively treating human diseases, remain to be addressed (Li et al., 2019).

Table 1: Techniques of Genome Editing

Genome Editing Technique	Method	Reference
CRISPR-Cas9	CRISPR-Cas9 works by using a molecule called RNA as a guide to precisely target and edit specific genes within an organism's DNA.	Xu et al., 2020
TALE nucleases	TALE nucleases work by using customizable proteins to target and edit specific DNA sequences in a highly precise manner.	Ousterout et al., 2016
Zinc-finger nucleases	Zinc-finger nucleases work by using engineered proteins called zinc-finger domains to target and edit specific DNA sequences with precision.	Chou et al., 2012

CRISPR-Cas9

CRISPR-Cas9 genome editing stands out as a revolutionary molecular technology that enables precise modifications to an organism's DNA. The term CRISPR refers to "Clustered Regularly Interspaced Short Palindromic Repeats," which are repetitive DNA sequences in the genomes of bacteria and other microorganisms, serving as a microbial immune system against previously encountered viruses. The central component of CRISPR-Cas9 editing is the Cas9 enzyme, functioning as molecular scissors. To utilize CRISPR-Cas9, scientists design a small RNA piece, known as "guide RNA" or "gRNA," with a sequence matching the DNA to be edited. This gRNA is engineered to be complementary to the target DNA sequence, ensuring specific binding to the intended location in the genome. Upon introducing the gRNA into a cell, it guides the Cas9 enzyme precisely to the DNA location requiring modification. Cas9 then acts as molecular scissors, making a cut at that specific point, triggering the cell's natural DNA repair mechanisms (Xu et al., 2020).

TALE nuclease

TALE nucleases operate by tailoring TALE proteins to identify and attach to a designated DNA sequence. When combined with a nuclease enzyme, they induce a double-stranded break at that particular location. Subsequently, the cell's repair mechanisms, known as Non-Homologous End Joining (NHEJ) or Homology-Directed Repair (HDR), either introduce errors or precise alterations to the DNA, thereby accomplishing genome editing. While TALE nucleases provide high specificity, their utilization demands careful ethical and safety considerations (Wu et al., 2020).

Zinc finger nucleases

Zinc finger nucleases (ZFNs) represent engineered proteins employed in genome editing. Comprising custom-designed zinc finger proteins that specifically bind to DNA sequences and a fused nuclease enzyme (typically derived from FokI endonuclease), ZFNs play a key role. Upon binding to the targeted DNA sequence, the nuclease induces a double-stranded break. The cell's inherent DNA repair mechanisms then mend the break through either error-prone Non-Homologous End Joining (NHEJ) or precise Homology-Directed Repair (HDR), leading to gene knockout or desired genetic alterations. While ZFNs offer meticulous genome editing, careful ethical and safety considerations are imperative in their application (Im et al., 2016)

Genome Editing for Disease Modelling and Gene Therapy

Chimeric genome editing tools like ZFNs, TALENs, and CRISPR/Cas9 facilitate precise gene modification by constructing custom components that guide these tools to specific DNA sequences within a targeted gene. In the case of ZFNs and TALENs, custom-designed proteins are engineered to bind to the target DNA, while the CRISPR/Cas9 system utilizes a synthetic guide RNA (gRNA) to direct the Cas9 enzyme to the intended location. Once at the targeted site, a double-stranded break (DSB) is initiated in the DNA. The cell then employs its innate repair mechanisms, such as Non-Homologous End Joining (NHEJ) or Homology-Directed Repair (HDR), to mend the DSB. Depending on the prevailing repair pathway, this results in either the knockout of the targeted gene or the precise introduction of desired genetic changes. This approach facilitates the exploration of gene function and the potential development of therapeutic strategies for genetic diseases (Breier et al., 2022).

Disease Covered

Cancer: Editing tools such as CRISPR/Cas9 have the potential to specifically target and modify genes linked to cancer. This application involves deactivating oncogenes, which promote cancer growth, or activating tumor suppressor genes, which inhibit cancer growth. Scientists are investigating the use of these tools for precise cancer therapies, personalized medicine, and the development of innovative strategies to target cancer cells with minimal impact on healthy cells (Breier et al., 2022).

Cardiovascular Diseases: Within the realm of cardiovascular diseases, gene editing offers the potential to rectify genetic mutations that make individuals susceptible to ailments such as hypertrophic cardiomyopathy or familial hypercholesterolemia. Additionally, scientists are exploring the application of gene editing to enhance cardiac regeneration and mend damaged heart tissue resulting from heart attacks (German et al., 2019).

Metabolic Diseases: Gene editing tools have the capability to rectify genetic mutations associated with metabolic disorders like phenylketonuria (PKU) or glycogen storage disorders. This correction of dysfunctional metabolic genes presents the opportunity for enduring therapeutic advantages. In the case of neurodegenerative diseases such as Alzheimer's, Parkinson's, or Huntington's disease, gene editing tools can focus on and alter genes linked to the progression of these disorders. Despite the substantial challenges in treating brain-related diseases, these tools show potential in addressing the fundamental genetic factors contributing to such conditions (Chandler et al., 2016).

Viral Diseases: Utilizing gene editing for the creation of therapies against viral diseases, like HIV, is under exploration. Scientists are investigating approaches to edit immune cells, rendering them resistant to viral infections. This exploration holds the potential for achieving functional cures or establishing long-term control over viral diseases (Kim et al., 2023).

Challenges

Gene editing technologies, notably CRISPR/Cas9, offer significant promise in tackling genetic diseases and advancing scientific exploration. Nevertheless, they come with challenges. A notable concern involves the potential for off-target effects, where these tools might unintentionally modify genes other than the intended target, introducing risks of unintended consequences. Achieving heightened levels of efficiency and precision in gene editing, particularly within intricate genomes, remains an ongoing hurdle. Moreover, delivering gene editing tools accurately and safely to target cells or tissues, especially in *in vivo* applications, presents a complex task. Ethical considerations also cast a significant shadow, given the technology's potential to alter the human germline, prompting questions about responsible and ethical usage of these potent tools. Thus, while the benefits are substantial, addressing these challenges is imperative to unlock the full potential of gene editing while ensuring safety, precision, and ethical standards are maintained (Liu et al., 2021; Yamaguchi et al., 2020).

Future Prospect

The future of genome editing is marked by tremendous potential across various domains. In medicine, ongoing advancements, especially in tools like CRISPR/Cas9, hold promise for personalized and precise therapies, potentially curing previously untreatable genetic diseases. Agriculture stands to benefit from genetically modified crops with improved traits, contributing to global food security. Additionally, genome editing has applications in synthetic biology, enabling the engineering of organisms for diverse purposes, from biofuel production to environmental remediation. However, ethical considerations remain crucial, necessitating robust regulatory frameworks to guide the responsible use of these technologies. While genome editing offers transformative possibilities, its realization depends on ethical practices and societal acceptance. In summary, genome editing is poised to shape the future of medicine, agriculture, and technology, but its success requires a balanced approach, combining scientific innovation with ethical responsibility.

Conclusion

In conclusion, gene editing technologies like CRISPR/Cas9, TELE and Zinc Finger nuclease represent a transformative frontier in genetics and biotechnology, offering the potential to address genetic diseases, enhances our understanding of biology, and revolutionizes medical treatments. However, they face notable challenges, including concerns about off-target effects, the need for greater efficiency and precision, delivery complexities, and profound ethical considerations. Despite these hurdles, researchers and society at large are actively engaged in advancing this field while navigating the ethical and regulatory landscapes. The future of gene editing holds immense promise, but its realization must be guided by a commitment to responsible innovation, safety, and ethical principles to harness its full potential for the benefit of humanity.

Acknowledgements

The authors express their sincere gratitude to the higher authorities of Swami Vivekananda University and the School of Life Sciences for their unwavering support. Thanks to the entire university for fostering an environment of excellence.

Conflict of Interest

The authors declare that there are no conflicts of interest.

References

- Breier, D., & Peer, D. (2022). Genome editing in cancer: Challenges and potential opportunities. *Bioactive materials*, 21, 394–402.
- Chandler, R. J., & Venditti, C. P. (2016). Gene Therapy for Metabolic Diseases. *Translational science of rare diseases*, 1(1), 73–89.
- Chou, S. T., Leng, Q., & Mixson, A. J. (2012). Zinc Finger Nucleases: Tailor-made for Gene Therapy. *Drugs of the future*, 37(3), 183–196.
- Gaj, T., Sirk, S. J., Shui, S. L., & Liu, J. (2016). Genome-Editing Technologies: Principles and Applications. *Cold Spring Harbor perspectives in biology*, 8(12), a023754.
- German, D. M., Mitalipov, S., Mishra, A., & Kaul, S. (2019). Therapeutic Genome Editing in Cardiovascular Diseases. *JACC. Basic to translational science*, 4(1), 122–131.
- Im, W., Moon, J., & Kim, M. (2016). Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders. *Journal of movement disorders*, 9(3), 136–143.
- Kim, T. H., & Lee, S. W. (2022). Therapeutic Application of Genome Editing Technologies in Viral Diseases. *International journal of molecular sciences*, 23(10), 5399.
- Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019). Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy. *Computational and structural biotechnology journal*, 17, 689–698.
- Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. *Precision clinical medicine*, 4(3), 179–191. <https://doi.org/10.1093/pccmedi/pbab014>

10. Ousterout, D. G., & Gersbach, C. A. (2016). The Development of TALE Nucleases for Biotechnology. *Methods in molecular biology (Clifton, N.J.)*, 1338, 27–42.
11. Wu, S. S., Li, Q. C., Yin, C. Q., Xue, W., & Song, C. Q. (2020). Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases. *Theranostics*, 10(10), 4374–4382.
12. Xu, Y., & Li, Z. (2020). CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. *Computational and structural biotechnology journal*, 18, 2401–2415.
13. Yamaguchi, T., Uchida, E., Okada, T., Ozawa, K., Onodera, M., Kume, A., Shimada, T., Takahashi, S., Tani, K., Nasu, Y., Mashimo, T., Mizuguchi, H., Mitani, K., & Maki, K. (2020). Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan. *Human gene therapy*, 31(19-20), 1043–1053.